AstraZeneca PLC Financials
ZEG Stock | 126.75 5.15 4.24% |
AstraZeneca |
Understanding current and past AstraZeneca PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AstraZeneca PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in AstraZeneca PLC's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in AstraZeneca PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AstraZeneca PLC. Check AstraZeneca PLC's Beneish M Score to see the likelihood of AstraZeneca PLC's management manipulating its earnings.
Instrument | Germany Stock View All |
Exchange | XETRA Stock Exchange |
ISIN | GB0009895292 |
Business Address | 1 Francis Crick |
Sector | Healthcare |
Industry | Drug Manufacturers-General |
Benchmark | Dow Jones Industrial |
Website | www.astrazeneca.com |
Phone | 44 20 3749 5000 |
You should never invest in AstraZeneca PLC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of AstraZeneca Stock, because this is throwing your money away. Analyzing the key information contained in AstraZeneca PLC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
AstraZeneca PLC Key Financial Ratios
AstraZeneca PLC's financial ratios allow both analysts and investors to convert raw data from AstraZeneca PLC's financial statements into concise, actionable information that can be used to evaluate the performance of AstraZeneca PLC over time and compare it to other companies across industries.Return On Equity | 0.0863 | |||
Return On Asset | 0.0555 | |||
Beta | 0.19 | |||
Z Score | 4.8 | |||
Last Dividend Paid | 2.9 |
AstraZeneca Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC is roughly 1.55 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.AstraZeneca PLC Systematic Risk
AstraZeneca PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AstraZeneca PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on AstraZeneca PLC correlated with the market. If Beta is less than 0 AstraZeneca PLC generally moves in the opposite direction as compared to the market. If AstraZeneca PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AstraZeneca PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AstraZeneca PLC is generally in the same direction as the market. If Beta > 1 AstraZeneca PLC moves generally in the same direction as, but more than the movement of the benchmark.
AstraZeneca PLC November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AstraZeneca PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AstraZeneca PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of AstraZeneca PLC based on widely used predictive technical indicators. In general, we focus on analyzing AstraZeneca Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AstraZeneca PLC's daily price indicators and compare them against related drivers.
Information Ratio | (0.26) | |||
Maximum Drawdown | 9.85 | |||
Value At Risk | (3.13) | |||
Potential Upside | 1.61 |
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.